Germany flag

Eitan Medical Wins 2021 Pharma Intelligence CPhI Awards

Eitan Medical’s SorrelTM Wearable Drug Delivery Platform Recognized for Excellence in Pharma ‘Packaging & Drug Delivery

NETANYA, Israel – December 20, 2021 – Eitan Medical, provider of connected infusion and drug delivery solutions, announced that it has received the 2021 ‘Excellence in Pharma: Packaging & Drug Delivery’ award from CPhI for its Sorrel™ wearable drug delivery platform.

CPhI Worldwide, one of the industry’s primary pharmaceutical exhibitions, announced the winners of its 18th annual CPhI Pharma Awards, hosted live on November 9th at an in-person ceremony in Milan. The award program recognizes innovative companies dedicated to driving the pharmaceutical industry forward, through groundbreaking solutions, technologies, and strategies.

“Despite the challenges of the past 18+ months, the pharmaceutical industry has shown both incredible resilience and a continued pursuit of innovation, something which is clearly reflected in the extremely high standard of entries for this year’s CPhI Pharma Awards,” said Tara Dougal, Head of Content & Insights, Informa Markets, in a statement about this year’s awards. “I’d like to thank our sponsor, Rentschler Biopharma, and especially our jury, who lent their time and expertise to assess the many entries we received. Lastly, I’d like to extend congratulations to all the nominees for their achievements, and of course to this year’s winners!”

Eitan Medical’s Sorrel™ platform, selected as the winner in CPHI’s Packaging and Drug Delivery category, offers a pre-filled, pre-loaded wearable drug delivery device for easy and efficient subcutaneous self-administration of large volume and high viscosity medications. Eitan Medical’s Pharmaceutical Solutions team developed Sorrel™ to address evolving drug delivery market needs, including the increasing use of large molecule biologic drugs. The platform is primary container agnostic, enabling pharma partners to utilize their primary container of choice, reducing complexities of integrating a new drug delivery platform, and minimizing time to market.

“Fast-tracked by COVID-19, the healthcare sector is in the process of shifting patient care away from the clinical setting and into the home, requiring providers to implement health technologies that are intuitive for patients to use independently,” said Ph.D. Andrei Yosef, General Manager Pharmaceutical Solution at Eitan Medical. “A primary challenge associated with homecare has been patient compliance and medication adherence. The ease with which patients can use the Sorrel™ device should tackle these challenges, and we are thrilled that our solution has been once again recognized for its patient-centric design approach.”

About Eitan Medical

Eitan Medical is reimagining drug delivery, with reliable innovations that put patients at the center of care, making drug delivery easier and safer than ever before. Patient safety and care are only the starting point, as Eitan Medical goes beyond- delivering connected, intuitive drug delivery and infusion solutions that are designed to improve patient and clinician quality of life across the continuum of care, including hospital, ambulatory, and home care environments. For over a decade, Eitan Medical has provided safe, intuitive, and flexible solutions that meet evolving drug delivery needs. Eitan Medical’s product lines include the Sapphire™ infusion platform, providing smart infusion therapy systems in hospital and ambulatory settings; the Sorrel™ wearable drug delivery platform, the patient-centric on-body injector for delivery of biologic treatments; and Avoset™, connected infusion systems for the home care market*

*The Sorrel™ and Avoset™ devices are under development.

Eitan Medical, Sapphire, Avoset, and Sorrel are trademarks or registered trademarks of Eitan Medical Ltd.

share:

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Cookies Usage

We use cookies to enhance site navigation, analyze website usage, assist in our third parties’ marketing efforts, and otherwise.

By using this site you agree to our use of cookies. For more information please read our Privacy Statement.

Sprechen Sie mit uns

Parlez avec nous